Literature DB >> 7680365

Efficient preparation of human monoclonal antibody-secreting heterohybridomas using peripheral B lymphocytes cultured in the CD40 system.

A Darveau1, M C Chevrier, S Néron, R Delage, R Lemieux.   

Abstract

The use of peripheral B lymphocytes in the successful preparation of human monoclonal antibodies by hybridoma technology is highly dependent on lymphocyte activation procedures. We studied the ability of peripheral human B lymphocytes cultured in vitro and activated through their CD40 antigen (CD40 system) (Banchereau et al., 1991) to form antibody-secreting heterohybridomas after fusion with murine X63Ag8.653 myeloma cells. The frequency of antibody-secreting heterohybridomas formation was greatly increased (15 times) by culture of B cells in the CD40 system. The CD40 system offers many advantages over other procedures of B lymphocyte activation representing a significant technological advance in the preparation of human monoclonal antibodies by standard hybridoma technology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7680365     DOI: 10.1016/0022-1759(93)90151-v

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Development of human monoclonal antibodies: A review.

Authors:  T Lindl
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

2.  Production and characterization of monoclonal IgM autoantibodies specific for the T-cell receptor.

Authors:  I F Robey; S F Schluter; D E Yocum; J J Marchalonis
Journal:  J Protein Chem       Date:  2000-01

3.  The natural antibody repertoire of sharks and humans recognizes the potential universe of antigens.

Authors:  Miranda K Adelman; Samuel F Schluter; John J Marchalonis
Journal:  Protein J       Date:  2004-02       Impact factor: 2.371

Review 4.  Exploring the native human antibody repertoire to create antiviral therapeutics.

Authors:  S K Dessain; S P Adekar; J D Berry
Journal:  Curr Top Microbiol Immunol       Date:  2008       Impact factor: 4.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.